Hedge Fund and Insider Trading News: Jeffrey Ubben, Tom Steyer, Chris Hohn, Coatue Management, Silver Lake Partners, Armistice Capital, Zscaler Inc (ZS), Canadian National Railway (CNI), and More

Blue Creek Capital Automates Investment Processes with SS&C Eze Eclipse Platform (The Trade)
Equity fund manager Blue Creek Capital Management has implemented SS&C’s Eze Eclipse as a front-to-back office platform to automate its investment processes for its China fund. Eze Eclipse will provide speed and flexibility required to bring together Blue Creek’s investment team located in Shanghai and its operations located in Hong Kong, SS&C said in a statement.

Vaxart Board Let Fund Insider Trade on Covid Vaccine: Suit (1) (Bloomberg Law)
Vaxart Inc.’s board was hit with a Delaware lawsuit claiming it helped a hedge fund linked to it, Armistice Capital LLC, make hundreds of millions on insider trades around news that Vaxart would be getting federal funding for its work on a Covid-19 vaccine. “Through their disloyal behavior, the board members have secured substantial sums for themselves and Armistice Capital, to the detriment of Vaxart,” the Chancery Court complaint says.

Zscaler Inc (ZS) President, CEO & Chairman Jagtar Singh Chaudhry Sold $8.7 Million of Shares (Guru Focus)
President, CEO & Chairman of Zscaler Inc., Jagtar Singh Chaudhry, sold 66,372 shares of ZS on 09/16/2020 at an average price of $131.72 a share. The total sale was $8.7 million. Zscaler Inc is a cloud security company. It engages in developing a platform incorporating core security functionalities needed to enable users to safely utilize authorized applications and services based on an organization’s policies.

The President & Chief Executive Officer of Canadian Railway (NYSE: CNI) is Buying Shares (Analyst Ratings)
Today, the President & Chief Executive Officer of Canadian Railway (CNI), Jean-Jacques Ruest, bought shares of CNI for $3.55M. Following Jean-Jacques Ruest’s last CNI Buy transaction on December 26, 2017, the stock climbed by 28.1%. This is Ruest’s first Buy trade following 19 Sell transactions.

Novocure (NVCR) COO Wilhelmus Cm Groenhuysen Sold $7.7 million of Shares (Guru Focus)
COO of Novocure, Wilhelmus Cm Groenhuysen, sold 75,868 shares of NVCR on 09/15/2020 at an average price of $101.53 a share. The total sale was $7.7 million. NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.